Top Biopharmaceutical Packaging Market Companies: A Detailed Profile

By /

Biopharmaceutical Packaging Market Companies

Biopharmaceutical Packaging Market Companies
  • Gerresheimer AG
  • Schott AG
  • Corning Incorporated
  • West Pharmaceutical Services
  • Stevanato Group
  • BD (Becton, Dickinson and Company
  • Amcor / Amcor Pharma
  • AptarGroup
  • SGD / SGD Pharma
  • Nipro Corporation
  • Catalent
  • PCI Pharma Services
  • Fisher Clinical Services / Thermo Fisher Scientific
  • Schreiner MediPharm
  • IMA Group

Gerresheimer AG

  • Company Name and Headquarters: Gerresheimer AG, headquartered in Düsseldorf, Germany.

  • Product Offerings Related to Biopharmaceutical Packaging: Gerresheimer is a leading global partner for the pharma, biotech, and cosmetic industries. Their biopharmaceutical packaging offerings include:

    • Syringes: Pre-fillable syringes (e.g., Gx RTF ClearJect, Gx RTF Luerlock, Gx RTF Gx Aseptic Syringes) for various drug delivery systems, including those for highly sensitive biologics.

    • Vials: Injection vials (e.g., Gx PharmaVials) made from borosilicate glass, designed for stability and compatibility with sensitive biopharmaceuticals.

    • Cartridges: Glass cartridges for insulin pens and other drug delivery devices.

    • Specialty Primary Packaging: Custom solutions for complex biologics, including high-quality plastic packaging (e.g., COP vials, syringes).

    • Drug Delivery Systems: Development and manufacturing of auto-injectors, pen injectors, and other sophisticated drug delivery devices.

  • Market Share and Estimated Revenue from Biopharmaceutical Packaging Segment: Gerresheimer is a significant player, particularly in glass primary packaging. While specific revenue for “biopharmaceutical packaging” isn’t broken out, their Plastics & Devices and Primary Packaging Glass divisions heavily contribute. Their annual revenue (2023) was approximately €1.99 billion. A substantial portion, likely exceeding 50-60%, is attributable to pharmaceutical packaging, with biopharmaceutical applications being a key growth driver.

  • Recent Developments, Partnerships, or Innovations:

    • Continuous expansion of their ready-to-fill (RTF) syringe and vial portfolio.

    • Investment in advanced manufacturing technologies for high-quality, sterile packaging.

    • Focus on sustainable packaging solutions.

    • Partnerships with biotech companies for custom device and packaging development.

    • Expansion of their GX® Gx® glass and polymer solutions for parenteral applications.

  • Competitive Positioning and Strategic Focus: Gerresheimer is positioned as a premium provider of high-quality, safe, and sophisticated packaging and drug delivery solutions. Their strategic focus is on innovation, expanding their RTF portfolio, leveraging their material expertise (glass and polymer), and growing in high-value segments like biologics, biosimilars, and injectables. They aim to be a “system and solution provider” rather than just a component supplier.

  • Key Customers or Industries Served: Global pharmaceutical companies, biotech firms, contract manufacturing organizations (CMOs), and contract development and manufacturing organizations (CDMOs) specializing in injectables, vaccines, insulin, and other sensitive biologics.

Schott AG

  • Company Name and Headquarters: Schott AG, headquartered in Mainz, Germany.

  • Product Offerings Related to Biopharmaceutical Packaging: Schott is a global leader in specialty glass and glass-ceramics, with a strong focus on pharmaceutical packaging. Their offerings include:

    • Vials: FIOLAX® glass vials (e.g., Schott TopLyo® for lyophilized drugs, Schott Vials DC for diagnostic containers, Schott Vials ClearSight® for enhanced inspection), particularly known for their hydrolytic resistance and dimensional stability.

    • Syringes: Syringes made from FIOLAX® glass, including Schott TopPac® pre-fillable syringes, suitable for sensitive biopharmaceuticals.

    • Cartridges: Glass cartridges for drug delivery devices.

    • Glass Tubing: A primary supplier of glass tubing (FIOLAX®) to other packaging manufacturers.

    • Schott Pharma (Spun-off Segment): While Schott AG still owns a majority stake, Schott Pharma now specifically focuses on pharmaceutical primary packaging.

  • Market Share and Estimated Revenue from Biopharmaceutical Packaging Segment: Schott is a dominant player in pharmaceutical glass packaging, especially for high-end applications. Schott Pharma, specifically, reported sales of €892 million in fiscal year 2022/2023. A very high percentage of this revenue comes directly from biopharmaceutical packaging, given their focus on injectable drugs. They are a market leader in syringes and vials for biologics.

  • Recent Developments, Partnerships, or Innovations:

    • Continued expansion of their iQ™ platform for intelligent, data-driven quality control in glass manufacturing.

    • Development of high-performance polymer solutions (e.g., using cyclic olefin copolymer – COC) for extreme pH ranges or highly viscous drugs.

    • Introduction of Schott EVERIC™ strong and pure vials, designed for improved resistance and reduced delamination.

    • Significant investments in increasing production capacity globally, particularly for high-value vials and syringes.

    • Strategic focus on ready-to-use (RTU) solutions.

  • Competitive Positioning and Strategic Focus: Schott is positioned at the premium end of the market, known for its superior glass quality (FIOLAX®), technical expertise, and innovation in sterile and high-performance packaging. Their strategic focus is on advanced drug containment solutions for complex and sensitive drugs, expanding their RTU portfolio, and maintaining their leadership in pharmaceutical glass.

  • Key Customers or Industries Served: Global pharmaceutical and biotech companies, vaccine manufacturers, CDMOs, and diagnostic companies.

Corning Incorporated

  • Company Name and Headquarters: Corning Incorporated, headquartered in Corning, New York, USA.

  • Product Offerings Related to Biopharmaceutical Packaging: Corning, renowned for its specialty glass and ceramics, entered the pharmaceutical packaging market with innovative solutions:

    • Corning Valor® Glass: A revolutionary borosilicate glass packaging solution designed for pharmaceutical use, aiming to significantly reduce particle contamination, delamination, and breakage. It is designed to be stronger and more chemically durable than conventional borosilicate glass.

    • Vials: Valor® Glass vials for various drug types, including sensitive biologics and vaccines.

    • Syringes & Cartridges: Valor® Glass technology is also being applied to syringes and cartridges.

  • Market Share and Estimated Revenue from Biopharmaceutical Packaging Segment: Corning is a newer entrant into the highly regulated pharmaceutical primary packaging space, but with significant potential. Their pharmaceutical technologies division, which includes Valor® Glass, is a growth area. Specific revenue figures for Valor® Glass alone are not publicly detailed, but it’s a strategic initiative expected to capture a substantial share, particularly in high-value biopharma. Corning’s Life Sciences segment (which includes pharmaceutical technologies) had sales of $1.1 billion in 2023, with Valor Glass contributing a growing portion.

  • Recent Developments, Partnerships, or Innovations:

    • Collaborations with leading pharmaceutical companies (e.g., Pfizer, Merck & Co., Inc.) for the adoption and scale-up of Valor® Glass.

    • Ongoing expansion of manufacturing capacity for Valor® Glass vials.

    • Development of Valor® Glass for next-generation drug delivery systems.

    • Focus on sustainability benefits due to the strength and durability of Valor® Glass.

  • Competitive Positioning and Strategic Focus: Corning is positioning Valor® Glass as a disruptive technology that addresses critical challenges in drug containment (e.g., drug-packaging interaction, manufacturing efficiency). Their strategic focus is on driving the adoption of Valor® Glass as the new standard for pharmaceutical packaging, particularly for high-value, sensitive biopharmaceuticals and vaccines, leveraging its superior strength, chemical durability, and reduced particulate risk.

  • Key Customers or Industries Served: Major global pharmaceutical companies, biotech firms, and vaccine manufacturers seeking to enhance drug safety, quality, and manufacturing efficiency.

West Pharmaceutical Services

  • Company Name and Headquarters: West Pharmaceutical Services, Inc., headquartered in Exton, Pennsylvania, USA.

  • Product Offerings Related to Biopharmaceutical Packaging: West is a global leader in injectable drug containment and delivery, with a strong focus on rubber components and integrated systems for biopharmaceuticals:

    • Vial Components: Stoppers and seals (e.g., NovaPure®, FluroTec® coated stoppers) made from high-quality elastomers, designed for compatibility with sensitive biologics, reduced leachables, and enhanced barrier properties.

    • Syringe Components: Plunger stoppers, tip caps, and needle shields (e.g., Daikyo Crystal Zenith® polymer components) for pre-filled syringes.

    • Cartridge Components: Components for drug cartridges.

    • Self-Injection Systems: Integrated solutions like the SmartDose® on-body injector, allowing for patient self-administration of biopharmaceuticals.

    • Reconstitution Systems: Systems for mixing lyophilized drugs.

    • High-End Polymer Solutions: Daikyo Crystal Zenith® (CZ) polymer vials, syringes, and cartridges for drugs with extreme pH or high sensitivity to glass.

  • Market Share and Estimated Revenue from Biopharmaceutical Packaging Segment: West is a dominant player in pharmaceutical elastomeric components for injectable drugs. Their sales in 2023 were $2.91 billion. The vast majority of this revenue comes from pharmaceutical packaging, with a significant and growing portion (estimated 70-80%) directly serving the biopharmaceutical market due to the high demand for injectable biologics and vaccines. Their NovaPure® and CZ lines are specifically targeted at biopharma.

  • Recent Developments, Partnerships, or Innovations:

    • Expansion of their NovaPure® product line for enhanced purity and consistency.

    • Further development and adoption of their Daikyo Crystal Zenith® platform for ultra-sensitive drugs.

    • Continued innovation in self-injection and connected health devices.

    • Investments in expanding global manufacturing capacity for high-value components.

    • Focus on integrated systems and digital solutions for drug delivery.

  • Competitive Positioning and Strategic Focus: West is positioned as a trusted partner for drug containment and delivery solutions, particularly for complex and sensitive injectable drugs. Their strategic focus is on offering high-quality, high-performance components and integrated systems, leveraging their material science expertise (elastomers and polymers), and expanding their footprint in advanced drug delivery, especially for biologics and biosimilars.

  • Key Customers or Industries Served: Global pharmaceutical companies, biotech firms, vaccine manufacturers, and CDMOs focused on injectable drugs, advanced therapies, and biologics.

Stevanato Group

  • Company Name and Headquarters: Stevanato Group S.p.A., headquartered in Piombino Dese, Italy.

  • Product Offerings Related to Biopharmaceutical Packaging: Stevanato Group is a leading global provider of integrated solutions for drug containment and delivery. Their biopharmaceutical packaging offerings include:

    • Vials: A wide range of high-quality glass vials (e.g., SG EZ-fill® vials, Alba® stoppers), including specialty vials for sensitive biologics and lyophilized drugs.

    • Syringes: Pre-fillable glass syringes (e.g., SG EZ-fill® syringes), catering to various drug viscosities and delivery needs.

    • Cartridges: Glass cartridges for pens and auto-injectors.

    • Plastic Solutions: Integrated polymer solutions, including advanced plastic vials and drug delivery devices.

    • Drug Delivery Systems: Development and manufacturing of complex drug delivery devices like auto-injectors and wearable devices.

    • Diagnostic Glass: Glass components for diagnostic applications.

    • Engineering Services: Provision of glass forming and inspection machinery to other packaging manufacturers.

  • Market Share and Estimated Revenue from Biopharmaceutical Packaging Segment: Stevanato Group is a significant player, particularly in glass primary packaging and integrated solutions. Their total revenue in 2023 was €1.02 billion. A very large portion (estimated 75-85%) of their revenue is from pharmaceutical packaging, with biopharmaceutical applications being a core driver due to their focus on high-quality vials, syringes, and advanced delivery systems.

  • Recent Developments, Partnerships, or Innovations:

    • Expansion of their SG EZ-fill® platform for ready-to-use vials, syringes, and cartridges, simplifying aseptic filling processes for pharma companies.

    • Strategic investments in increasing production capacity for high-value products.

    • Development of advanced polymer solutions for specific drug needs.

    • Collaborations with pharmaceutical companies on custom drug delivery device development.

    • Focus on integrated solutions combining primary packaging with advanced delivery systems.

  • Competitive Positioning and Strategic Focus: Stevanato Group is positioned as an integrated solutions provider, offering both high-quality primary packaging and advanced drug delivery systems. Their strategic focus is on being a “one-stop-shop” for pharmaceutical companies, leveraging their expertise in glass, plastics, and precision engineering to serve the growing injectables and biopharmaceutical market with a strong emphasis on RTU solutions.

  • Key Customers or Industries Served: Global pharmaceutical companies, biotech firms, vaccine manufacturers, CDMOs, and diagnostic companies.

BD (Becton, Dickinson and Company)

  • Company Name and Headquarters: BD (Becton, Dickinson and Company), headquartered in Franklin Lakes, New Jersey, USA.

  • Product Offerings Related to Biopharmaceutical Packaging: BD is a global medical technology company with a substantial presence in drug delivery, particularly pre-fillable syringes:

    • Pre-fillable Syringes: A market leader in glass and plastic pre-fillable syringes (e.g., BD Hypak™ for Biologics, BD UltraSafe™ Passive Needle Guard), essential for vaccines, biologics, and other injectable drugs.

    • Safety Devices: Integrated safety features for syringes (e.g., needle shields, auto-disable features).

    • Self-Injection Systems: Components and finished devices for patient self-administration.

    • Vials & Cartridges: While primarily known for syringes, they also offer related components and solutions.

    • Medical Devices: Broad portfolio of medical devices beyond drug packaging, but their pharmaceutical systems division is highly relevant.

  • Market Share and Estimated Revenue from Biopharmaceutical Packaging Segment: BD is a dominant player in the pre-fillable syringe market. Their Medical segment, which includes Pharmaceutical Systems, had revenues of $9.0 billion in 2023. The Pharmaceutical Systems unit specifically generated around $2.1 billion in 2023, with the majority directly serving the biopharmaceutical and vaccine markets. They hold a significant share of the global pre-fillable syringe market.

  • Recent Developments, Partnerships, or Innovations:

    • Continuous innovation in pre-fillable syringe technology, including new materials and coatings for drug stability.

    • Expansion of their BD Hypak™ for Biologics portfolio.

    • Investments in increasing manufacturing capacity for syringes globally, especially for pandemic preparedness.

    • Development of advanced drug delivery systems and digital health solutions.

    • Focus on enhancing user safety and convenience in drug administration.

  • Competitive Positioning and Strategic Focus: BD is positioned as a global leader in drug delivery solutions, particularly known for its high-quality, reliable, and innovative pre-fillable syringes. Their strategic focus is on expanding their leadership in this segment, catering to the growing demand for biologics and vaccines, and developing integrated systems that improve drug safety, efficacy, and patient experience.

  • Key Customers or Industries Served: Global pharmaceutical companies, biotech firms, vaccine manufacturers, CDMOs, and healthcare providers.

Amcor / Amcor Pharma

  • Company Name and Headquarters: Amcor plc, headquartered in Warmley, Bristol, UK (with administrative center in Zurich, Switzerland). Amcor Pharma is a dedicated business unit.

  • Product Offerings Related to Biopharmaceutical Packaging: Amcor is a global leader in responsible packaging solutions, with a strong focus on flexible and rigid packaging:

    • Blister Packaging: High-barrier flexible and rigid films for blister packs (e.g., Amcor Aluseal®, Amcor Formpack®), protecting solid-dose biopharmaceuticals.

    • Sachets and Pouches: Flexible packaging for powders, liquids, or devices, including high-barrier materials for sterile applications.

    • Laminates: High-performance laminates for various pharmaceutical applications requiring moisture, oxygen, and light barriers.

    • Child-Resistant & Senior-Friendly Packaging: Solutions addressing regulatory requirements for patient safety.

    • Sterile Barrier Systems: Packaging for sterile medical devices and combination products used in biopharma.

    • Recyclable Packaging: Development of more sustainable packaging options for the pharmaceutical industry.

  • Market Share and Estimated Revenue from Biopharmaceutical Packaging Segment: Amcor is one of the largest packaging companies globally, with total sales of $14.7 billion in 2023. While not exclusively biopharmaceutical, their “Healthcare” segment is a significant contributor. Amcor Pharma is a dedicated unit for this sector. A substantial portion of their healthcare packaging, particularly high-barrier flexible films and foils, is used for biopharmaceuticals (e.g., lyophilized drugs, sensitive tablets, sterile devices).

  • Recent Developments, Partnerships, or Innovations:

    • Continued focus on developing sustainable and recyclable pharmaceutical packaging solutions.

    • Innovation in high-barrier films for extended shelf life and drug protection.

    • Expansion of digital printing capabilities for enhanced traceability and anti-counterfeiting.

    • Investments in advanced material science for improved barrier properties.

    • Partnerships to develop circular economy solutions for pharmaceutical packaging.

  • Competitive Positioning and Strategic Focus: Amcor is positioned as a global leader in innovative and sustainable packaging solutions, leveraging its extensive material science and manufacturing expertise. Their strategic focus in biopharma is on providing high-performance, compliant, and sustainable flexible and rigid packaging, enhancing drug protection, patient safety, and brand integrity.

  • Key Customers or Industries Served: Global pharmaceutical companies, biotech firms, medical device manufacturers, CDMOs, and contract packers.

AptarGroup

  • Company Name and Headquarters: AptarGroup, Inc., headquartered in Crystal Lake, Illinois, USA.

  • Product Offerings Related to Biopharmaceutical Packaging: Aptar is a global leader in drug delivery systems, particularly focused on innovative dispensing solutions for various routes of administration:

    • Injectable Drug Delivery: Components and devices for pre-filled syringes (e.g., stoppers, plungers) and vials (e.g., elastomeric stoppers, seals).

    • Nasal Delivery Systems: Metered-dose pumps and devices for nasal administration of drugs (e.g., for vaccines, biologics).

    • Pulmonary Delivery Systems: Dry powder inhalers (DPIs) and metered-dose inhalers (MDIs) components.

    • Ophthalmic Delivery Systems: Preservative-free eye drop dispensers (e.g., Aptar Ophthalmic Squeeze Dispenser).

    • Elastomeric Components: High-quality rubber stoppers and plungers for vials and syringes, including advanced coatings.

    • Active Packaging: Solutions that absorb moisture or oxygen to protect sensitive drugs.

  • Market Share and Estimated Revenue from Biopharmaceutical Packaging Segment: Aptar is a significant player in drug delivery devices and components. Their Pharma segment generated sales of $1.56 billion in 2023. A very high percentage of this revenue is directly linked to biopharmaceutical packaging and delivery, particularly through their injectable, nasal, and ophthalmic solutions for biologics and advanced therapies.

  • Recent Developments, Partnerships, or Innovations:

    • Continuous innovation in preservative-free multi-dose ophthalmic dispensers.

    • Development of advanced elastomeric components with improved compatibility for sensitive biologics.

    • Expansion of their digital health solutions and connected device portfolio.

    • Investments in sterile manufacturing capabilities.

    • Partnerships with pharmaceutical companies for co-development of drug delivery platforms.

  • Competitive Positioning and Strategic Focus: Aptar is positioned as an innovation leader in drug delivery, offering complex dispensing and sealing solutions for various drug forms. Their strategic focus in biopharma is on providing patient-friendly, safe, and effective delivery systems, expanding their portfolio for biologics, and leveraging their expertise in materials and design for critical applications across different routes of administration.

  • Key Customers or Industries Served: Global pharmaceutical companies, biotech firms, generic drug manufacturers, and CDMOs.

SGD / SGD Pharma

  • Company Name and Headquarters: SGD Pharma, headquartered in Puteaux, France (formerly part of SGD Group).

  • Product Offerings Related to Biopharmaceutical Packaging: SGD Pharma is a global leader in glass primary packaging for the pharmaceutical industry:

    • Vials: A comprehensive range of molded and tubular glass vials (e.g., Clear Vials, Amber Vials) for injectable drugs, including biologics and vaccines. They are known for their Sterinity platform of Ready-to-Use (RTU) vials (SGD Pharma EasyLyo® and EasyFill®).

    • Bottles: Glass bottles for oral liquid and solid dose medications.

    • Flint & Amber Glass: Expertise in both clear (flint) and amber glass to protect light-sensitive drugs.

    • Controlled Hydrolytic Resistance: Products designed to meet stringent pharmacopoeia standards for chemical resistance.

  • Market Share and Estimated Revenue from Biopharmaceutical Packaging Segment: SGD Pharma is a prominent global manufacturer of pharmaceutical glass vials and bottles. While specific market share data for biopharma is not explicitly disclosed, their focus on injectable vials means a significant portion of their revenue directly supports the biopharmaceutical market. They have a strong presence in Europe and Asia. Their annual revenue (estimated) is in the range of €350-450 million.

  • Recent Developments, Partnerships, or Innovations:

    • Expansion of the Sterinity Ready-to-Use (RTU) vial portfolio (EasyLyo® for lyophilized products and EasyFill® for liquids).

    • Investments in new manufacturing lines to increase capacity for high-quality vials.

    • Focus on sustainability through reduced energy consumption and circular economy initiatives.

    • Development of enhanced surface treatments for improved drug stability.

  • Competitive Positioning and Strategic Focus: SGD Pharma is positioned as a reliable, high-quality supplier of glass primary packaging for the pharmaceutical industry, with a strong emphasis on compliance and innovation. Their strategic focus is on expanding their RTU vial solutions, serving the growing injectable drug market, and maintaining their leadership in glass quality and manufacturing efficiency.

  • Key Customers or Industries Served: Global pharmaceutical companies, biotech firms, vaccine manufacturers, CDMOs, and generic drug manufacturers.

Nipro Corporation

  • Company Name and Headquarters: Nipro Corporation, headquartered in Osaka, Japan.

  • Product Offerings Related to Biopharmaceutical Packaging: Nipro is a global manufacturer of pharmaceutical packaging, medical devices, and pharmaceutical products. Their packaging division offers:

    • Vials: Glass vials, including specialty vials for lyophilized drugs and sensitive biologics.

    • Syringes: Pre-fillable glass syringes, including the Nipro Dosi-Fuser™ system and other advanced syringe solutions.

    • Cartridges: Glass cartridges for drug delivery systems.

    • Ampoules: Glass ampoules for parenteral applications.

    • Plastic Packaging: Some plastic primary packaging solutions.

    • Glass Tubing: Manufacturing of pharmaceutical glass tubing.

  • Market Share and Estimated Revenue from Biopharmaceutical Packaging Segment: Nipro is a significant global player, particularly strong in Asia and growing in other regions. Their total revenue for fiscal year 2023 was approximately JPY 485 billion (~$3.2 billion). The “Pharmaceutical Packaging” segment contributes a substantial portion, with pre-fillable syringes and vials for injectables being a key driver, directly serving the biopharmaceutical market.

  • Recent Developments, Partnerships, or Innovations:

    • Expansion of global manufacturing capacity for pre-fillable syringes and vials.

    • Introduction of new coating technologies for improved drug compatibility and reduced protein adsorption.

    • Focus on developing integrated drug delivery systems.

    • Strategic investments in R&D for advanced glass and polymer solutions.

  • Competitive Positioning and Strategic Focus: Nipro is positioned as a comprehensive provider of pharmaceutical primary packaging with a strong emphasis on quality, precision, and innovation. Their strategic focus is on expanding their global footprint, particularly in high-growth segments like pre-fillable syringes and vials for biologics, leveraging their integrated capabilities from glass tubing to finished packaging.

  • Key Customers or Industries Served: Global pharmaceutical companies, biotech firms, vaccine manufacturers, and CDMOs.

View Full Report

Catalent

  • Company Name and Headquarters: Catalent, Inc., headquartered in Somerset, New Jersey, USA.

  • Product Offerings Related to Biopharmaceutical Packaging: Catalent is a leading global CDMO (Contract Development and Manufacturing Organization). While primarily a service provider, their offerings include integrated packaging services that are critical for biopharmaceuticals:

    • Clinical and Commercial Packaging: Full-service packaging, including secondary packaging for vials, syringes, and other primary containers.

    • Sterile Fill/Finish: Aseptic filling of sterile liquids and lyophilized products into vials and syringes, a core service for biopharmaceuticals. This includes container closure systems.

    • Blister Packaging: Packaging for oral solid dose biopharmaceuticals.

    • Cold Chain Packaging: Specialized packaging solutions to maintain ultra-low temperatures for sensitive biologics during storage and transport.

    • Serialization and Traceability: Implementation of regulatory-compliant serialization for drug products.

    • Custom Kitting: Assembly of syringes with safety devices, auto-injectors, or other components.

  • Market Share and Estimated Revenue from Biopharmaceutical Packaging Segment: Catalent is a major CDMO, with total revenue of $4.28 billion in 2023. While not a “packaging manufacturer” in the traditional sense, their comprehensive integrated services, particularly sterile fill/finish and secondary packaging for injectables, make them a key player in the biopharmaceutical packaging ecosystem. A very significant portion of their revenue comes from biologics and sterile products, which inherently includes the packaging component. Their Biologics segment is a primary growth driver.

  • Recent Developments, Partnerships, or Innovations:

    • Significant investments in expanding sterile fill/finish capacity globally.

    • Acquisitions to enhance capabilities in biologics and advanced therapies.

    • Development of advanced cold chain solutions for gene therapies and mRNA vaccines.

    • Focus on integrated manufacturing and packaging solutions to streamline the supply chain.

    • Implementation of advanced automation in packaging lines.

  • Competitive Positioning and Strategic Focus: Catalent is positioned as an end-to-end partner for biopharmaceutical development, manufacturing, and integrated packaging. Their strategic focus is on leveraging their deep expertise in biologics and sterile manufacturing to provide comprehensive solutions, from early-stage development to commercial supply, including all necessary primary and secondary packaging.

  • Key Customers or Industries Served: Global pharmaceutical companies, biotech firms (especially small to mid-sized), and academic institutions.

PCI Pharma Services

  • Company Name and Headquarters: PCI Pharma Services, headquartered in Philadelphia, Pennsylvania, USA.

  • Product Offerings Related to Biopharmaceutical Packaging: PCI Pharma Services is a leading CDMO and contract packaging organization, offering integrated solutions for clinical and commercial supply:

    • Sterile Fill/Finish & Lyophilization: Aseptic filling into vials and syringes, including lyophilization services, which are critical for many biopharmaceuticals.

    • Clinical Packaging & Labeling: Specialized packaging for clinical trials, including cold chain and ultra-cold chain capabilities.

    • Commercial Packaging: Secondary packaging for a wide range of primary containers (vials, syringes, blisters, bottles).

    • Cold Chain Logistics: Comprehensive cold chain packaging, storage, and distribution services for temperature-sensitive biologics.

    • Serialization & Track and Trace: Implementation of regulatory-compliant serialization solutions.

    • Device Assembly: Assembly of auto-injectors, pen devices, and other combination products.

    • Blister Packaging: High-barrier blister packaging for oral solids.

  • Market Share and Estimated Revenue from Biopharmaceutical Packaging Segment: PCI Pharma Services is a major global player in contract packaging and manufacturing. While exact revenue solely for biopharmaceutical packaging isn’t published, a substantial portion of their overall revenue (estimated in the range of $800M – $1B annually) is derived from services for biopharmaceuticals, especially their sterile fill/finish and cold chain capabilities.

  • Recent Developments, Partnerships, or Innovations:

    • Significant expansion of sterile fill/finish and lyophilization capacity.

    • Acquisitions to enhance global footprint and service offerings (e.g., in advanced therapies).

    • Continuous investment in cold chain infrastructure and packaging technologies.

    • Development of advanced serialization and aggregation solutions.

    • Focus on providing integrated solutions across the drug lifecycle, from clinical to commercial.

  • Competitive Positioning and Strategic Focus: PCI Pharma Services is positioned as a trusted partner for complex and sensitive drug products, offering end-to-end services. Their strategic focus in biopharma is on providing robust sterile manufacturing, packaging, and supply chain solutions, leveraging their expertise in cold chain, serialization, and device assembly to meet the unique needs of biologics and advanced therapies.

  • Key Customers or Industries Served: Global pharmaceutical companies, biotech firms (from emerging to large), and academic research institutions.

Fisher Clinical Services / Thermo Fisher Scientific

  • Company Name and Headquarters: Fisher Clinical Services is a brand within Thermo Fisher Scientific, Inc., headquartered in Waltham, Massachusetts, USA.

  • Product Offerings Related to Biopharmaceutical Packaging: Fisher Clinical Services specializes in clinical trial supply chain management, which includes critical packaging services for biopharmaceuticals:

    • Clinical Packaging & Labeling: Design, assembly, and labeling of primary and secondary packaging for clinical trial materials, including vials, syringes, and various drug forms.

    • Cold Chain Packaging & Logistics: Extensive expertise in ultra-low temperature, cold, and controlled room temperature packaging, storage, and global distribution for highly sensitive biologics and advanced therapies.

    • Serialization & Randomization: Implementation of clinical trial randomization schemes and serialization.

    • Kitting & Device Assembly: Assembly of clinical trial kits and combination products.

    • Comparator Sourcing: Sourcing and packaging of comparator drugs.

    • Ancillary Supply: Packaging and distribution of ancillary materials needed for clinical trials.

  • Market Share and Estimated Revenue from Biopharmaceutical Packaging Segment: Thermo Fisher Scientific is a global giant in scientific services, with total revenue of $42.8 billion in 2023. Fisher Clinical Services is a leading player in clinical trial logistics and packaging. While specific revenue for “biopharmaceutical clinical packaging” isn’t isolated, it’s a very significant component of Fisher Clinical Services’ operations, supporting the massive R&D pipelines of biotech and pharma, especially for biologics which dominate clinical trials.

  • Recent Developments, Partnerships, or Innovations:

    • Continuous expansion of global clinical supply chain network and storage capacity.

    • Investments in advanced cold chain technologies and packaging materials.

    • Integration of digital solutions for clinical trial management and supply chain visibility.

    • Focus on optimizing speed and flexibility in clinical trial supply to accelerate drug development.

    • Expansion of capabilities for cell and gene therapy clinical supply.

  • Competitive Positioning and Strategic Focus: Fisher Clinical Services is positioned as a global leader in clinical trial supply, offering end-to-end solutions. Their strategic focus is on leveraging their global network, cold chain expertise, and regulatory knowledge to provide seamless and compliant packaging and logistics for clinical trials, particularly for complex and sensitive biopharmaceuticals and advanced therapies.

  • Key Customers or Industries Served: Global pharmaceutical companies, biotech firms, academic research organizations, and CDMOs engaged in clinical development.

Schreiner MediPharm

  • Company Name and Headquarters: Schreiner MediPharm (a business unit of Schreiner Group GmbH & Co. KG), headquartered in Oberschleißheim, Germany.

  • Product Offerings Related to Biopharmaceutical Packaging: Schreiner MediPharm specializes in innovative functional labels and smart packaging solutions for the pharmaceutical and medical industries:

    • Labels for Vials & Syringes: Specialty labels (e.g., Pharma-Tac® for easy detachment, Flexi-Cap for tamper protection) designed for small diameters, temperature resistance, and high-quality printing.

    • Tamper-Evident Labels: Solutions to protect against counterfeiting and ensure product integrity.

    • Anti-Counterfeiting Solutions: Integrated security features (e.g., holograms, invisible inks, digital codes) into labels.

    • Smart Labels & Digital Solutions: Labels with integrated NFC/RFID chips (e.g., for patient adherence, supply chain tracking) and smart packaging solutions for real-time monitoring.

    • Blister Pack Labels: Labels for patient information and adherence.

    • Integrated Solutions: Labels that combine multiple functions (e.g., patient information, authentication, temperature indication).

  • Market Share and Estimated Revenue from Biopharmaceutical Packaging Segment: Schreiner MediPharm is a niche but leading player in functional labels for pharmaceuticals. While specific revenue is not publicly disclosed, their specialized solutions are widely adopted in the biopharmaceutical sector due to the high value and sensitivity of these drugs, which require robust security, information, and often cold chain monitoring.

  • Recent Developments, Partnerships, or Innovations:

    • Continuous innovation in smart labels with integrated NFC/RFID technology for patient interaction and supply chain visibility.

    • Development of new anti-counterfeiting features and authentication technologies.

    • Expansion of their portfolio for combination products and medical devices.

    • Focus on sustainable label materials and processes.

    • Partnerships to integrate their label solutions with digital health platforms.

  • Competitive Positioning and Strategic Focus: Schreiner MediPharm is positioned as an innovation leader in functional labels and smart packaging, providing solutions that enhance drug safety, patient adherence, and supply chain security. Their strategic focus is on developing high-tech, multi-functional labels that address the specific challenges of biopharmaceuticals, including counterfeiting, temperature monitoring, and patient information.

  • Key Customers or Industries Served: Global pharmaceutical companies, biotech firms, medical device manufacturers, and CDMOs.

IMA Group

  • Company Name and Headquarters: IMA S.p.A. (IMA Group), headquartered in Ozzano dell’Emilia, Italy.

  • Product Offerings Related to Biopharmaceutical Packaging: IMA Group is a world leader in the design and manufacture of automatic machines for the processing and packaging of pharmaceutical products:

    • Aseptic Filling & Freeze-Drying Equipment: Machines for sterile filling of vials, syringes, and cartridges, including lyophilization (freeze-drying) equipment, essential for many biopharmaceuticals.

    • Blister Packaging Machines: High-speed machines for forming, filling, and sealing blister packs.

    • Cartoning Machines: Machines for secondary packaging, including serialization and aggregation.

    • Tablet & Capsule Processing Machines: Equipment for solid dose manufacturing.

    • Sterilization Systems: Machines for sterilizing packaging components.

    • Robotics & Automation: Advanced automation solutions for pharmaceutical manufacturing and packaging lines.

  • Market Share and Estimated Revenue from Biopharmaceutical Packaging Segment: IMA Group is a dominant force in pharmaceutical processing and packaging machinery. Their total revenue in 2022 was €2.1 billion. While they don’t produce the packaging materials themselves, their machines are absolutely critical for filling and packaging biopharmaceuticals into their primary and secondary containers. The biopharmaceutical sector (especially sterile filling and freeze-drying) is a major growth area for their machinery sales.

  • Recent Developments, Partnerships, or Innovations:

    • Development of advanced aseptic processing and containment solutions for high-potency drugs and biologics.

    • Introduction of new, faster, and more efficient freeze-drying equipment.

    • Integration of AI and digital technologies for smart factories and predictive maintenance.

    • Focus on sustainable machine design and reduced energy consumption.

    • Acquisitions to expand capabilities in specific areas of pharmaceutical processing and packaging.

  • Competitive Positioning and Strategic Focus: IMA Group is positioned as a global technology leader, providing innovative and reliable machinery for the entire pharmaceutical manufacturing and packaging process. Their strategic focus in biopharma is on offering cutting-edge solutions for aseptic fill/finish, lyophilization, and secondary packaging, enabling pharmaceutical companies to efficiently and safely produce complex and sensitive biopharmaceuticals.

  • Key Customers or Industries Served: Global pharmaceutical companies, biotech firms, CDMOs, and generic drug manufacturers who operate their own manufacturing and packaging facilities.

Contact Us

Related Posts

Scroll to Top